“Due to high interest in potential new therapies in the immuno-oncology field, either as monotherapy or in combination, the Company is currently engaged in partnering discussions with several parties and hopes for a positive outcome from these negotiations during 2019.”
RE: Makin family would never accept...20 Feb 2019 22:25
“I don't think JD would pay a premium like +100% or +200%”
What did they do on Monday when they paid 75p a share? The market price then was 30p and had been under that more often than not over the last month or so.